Details

Autor(en) / Beteiligte

• Brestrich, Gordon
• Hagemann, Christine
• Diesing, Joanna
• Kossack, Nils
• Stark, James H.
• Pilz, Andreas
• Angulo, Frederick J.
• Yu, Holly
• Suess, Jochen

Titel

Incidence of Lyme Borreliosis in Germany: A retrospective observational healthcare claims study

Ist Teil von

• Ticks and tick-borne diseases, 2024-05, Vol.15 (3), p.102326-102326, Article 102326

Ort / Verlag

Netherlands: Elsevier GmbH

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Claims algorithm using medical codes, antibiotic prescription and lab test order.Incidence of medically–attended Lyme borreliosis (LB) was 195.7–254.5/100,000 population per year.92.2% of cases were localized disease, while 7.8% were disseminated disease.Hospitalization rate was high in disseminated LB (18%–50% by manifestation).LB is endemic in all German federal states. Lyme borreliosis (LB) is the most common tick–borne disease in Germany. Although the incidence of LB in Germany has been assessed in several studies, those studies either used data from statutory surveillance, which frequently underreport cases, or data from health claims databases, which may overestimate cases due to non–specific LB case definitions. Here, using a more specific case definition, we describe the incidence of medically–attended LB by disease manifestation, age group, and federal state for the period 2015–2019. Both inpatient and outpatient cases were analyzed from a claims database. To be eligible for inclusion, patients were required to have an LB specific ICD–10 GM diagnosis code plus an antibiotic prescription, and for disseminated manifestations, a laboratory test order additionally. LB cases were classified as erythema migrans (EM), or disseminated disease including Lyme arthritis (LA), Lyme neuroborreliosis (LNB), and all other disease manifestations (OTH). Between 2015 and 2019, the incidence of medically–attended LB cases ranged from 195.7/100,000 population per year (95% confidence interval [CI], 191.0 – 200.5) to 254.5/100,000 population per year (95% CI, 249.0 – 260.0) per year. The majority of cases (92.2%) were EM, while 2.8% presented as LA, 3.8% as LNB, and 1.2% as OTH. For both EM and disseminated disease, the incidence peaked in children aged 5–9 years and in older adults. By federal state, the incidence of medically–attended EM ranged from 74.4/100,000 population per year (95% CI, 71.9 – 77.0) per year in Hamburg, to 394.1/100,000 population per year (95% CI, 370.7 – 417.6) per year in Saxony, whereas for medically–attended disseminated disease, the highest incidence was in Thuringia, Saxony, and Bavaria (range: 22.0 [95% CI, 19.9 – 24.0] to 35.7 [95% CI, 34.7 – 36.7] per 100,000 population per year). This study comprehensively estimated the incidence of all manifestations of medically–attended LB and showed a high incidence of LB throughout Germany. Results from the study support performing epidemiological studies in all federal states to measure the burden of LB and to invest in public health interventions for prevention.